TY - JOUR
T1 - ELABELA plasma concentrations are increased in women with late-onset preeclampsia
AU - Panaitescu, Bogdan
AU - Romero, Roberto
AU - Gomez-Lopez, Nardhy
AU - Pacora, Percy
AU - Erez, Offer
AU - Vadillo-Ortega, Felipe
AU - Yeo, Lami
AU - Hassan, Sonia S.
AU - Hsu, Chaur Dong
N1 - Publisher Copyright:
©, This work was authored as part of the Contributor's official duties as an Employee of the United States Government and is therefore a work of the United States Government. In accordance with 17 U.S.C. 105, no copyright protection is available for such works under U.S. Law.
PY - 2020/1/2
Y1 - 2020/1/2
N2 - Objective: ELABELA is a newly discovered peptide hormone that appears to be implicated in the mechanisms leading to preeclampsia, independently of angiogenic factors. The aim of the current study was to investigate whether women with early- or late-onset preeclampsia have altered ELABELA plasma concentrations compared to gestational-age-matched normal pregnant women. Methods: This retrospective cross-sectional study focused on the maternal plasma samples collected from 232 women with a singleton pregnancy who were allocated into the following groups: (1) early-onset preeclampsia (<34 weeks of gestation, N = 56); (2) late-onset preeclampsia (≥34 weeks of gestation, N = 57); and (3) gestational-age-matched controls with a normal pregnancy [(<34 weeks of gestation, N = 59); (≥34 weeks of gestation, N = 60)]. ELABELA plasma concentrations were determined using a validated enzyme immunoassay. Results: (1) ELABELA plasma concentrations are higher in patients with late-onset preeclampsia compared with those from gestational-age-matched controls with a normal pregnancy [median: 7.99 ng/mL (IQR, 5.3–13.95 ng/mL) versus median: 4.17 ng/mL (IQR, 3–11.19 ng/mL), p =.001]; (2) ELABELA plasma concentrations in patients with early-onset preeclampsia do not differ from those of normal pregnant women [median: 6.09 ng/mL (IQR, 2.8–10.66 ng/mL) versus median: 4.02 ng/mL (IQR, 3.26–7.49), p =.32]; and (3) ELABELA plasma concentrations are higher in patients with late-onset preeclampsia compared to those with early-onset preeclampsia [median: 7.99 ng/mL (IQR, 5.3–13.95 ng/mL) versus median: 6.09 ng/mL (IQR, 2.8–10.66 ng/mL), p =.01]. Conclusion: ELABELA plasma concentrations are higher in patients with late-onset preeclampsia than in those with a normal pregnancy. However, women with early-onset preeclampsia have similar ELABELA plasma concentrations to those with a normal pregnancy. These findings provide insight into the ELABELA axis during the human syndrome of preeclampsia. In addition, these data support the concept that different pathophysiologic mechanisms are implicated in early- and late-onset preeclampsia.
AB - Objective: ELABELA is a newly discovered peptide hormone that appears to be implicated in the mechanisms leading to preeclampsia, independently of angiogenic factors. The aim of the current study was to investigate whether women with early- or late-onset preeclampsia have altered ELABELA plasma concentrations compared to gestational-age-matched normal pregnant women. Methods: This retrospective cross-sectional study focused on the maternal plasma samples collected from 232 women with a singleton pregnancy who were allocated into the following groups: (1) early-onset preeclampsia (<34 weeks of gestation, N = 56); (2) late-onset preeclampsia (≥34 weeks of gestation, N = 57); and (3) gestational-age-matched controls with a normal pregnancy [(<34 weeks of gestation, N = 59); (≥34 weeks of gestation, N = 60)]. ELABELA plasma concentrations were determined using a validated enzyme immunoassay. Results: (1) ELABELA plasma concentrations are higher in patients with late-onset preeclampsia compared with those from gestational-age-matched controls with a normal pregnancy [median: 7.99 ng/mL (IQR, 5.3–13.95 ng/mL) versus median: 4.17 ng/mL (IQR, 3–11.19 ng/mL), p =.001]; (2) ELABELA plasma concentrations in patients with early-onset preeclampsia do not differ from those of normal pregnant women [median: 6.09 ng/mL (IQR, 2.8–10.66 ng/mL) versus median: 4.02 ng/mL (IQR, 3.26–7.49), p =.32]; and (3) ELABELA plasma concentrations are higher in patients with late-onset preeclampsia compared to those with early-onset preeclampsia [median: 7.99 ng/mL (IQR, 5.3–13.95 ng/mL) versus median: 6.09 ng/mL (IQR, 2.8–10.66 ng/mL), p =.01]. Conclusion: ELABELA plasma concentrations are higher in patients with late-onset preeclampsia than in those with a normal pregnancy. However, women with early-onset preeclampsia have similar ELABELA plasma concentrations to those with a normal pregnancy. These findings provide insight into the ELABELA axis during the human syndrome of preeclampsia. In addition, these data support the concept that different pathophysiologic mechanisms are implicated in early- and late-onset preeclampsia.
KW - Apela
KW - maternal vascular malperfusion
KW - maternal vascular underperfusion
KW - placenta
KW - pregnancy
KW - preterm delivery
UR - http://www.scopus.com/inward/record.url?scp=85050562958&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85050562958&partnerID=8YFLogxK
U2 - 10.1080/14767058.2018.1484089
DO - 10.1080/14767058.2018.1484089
M3 - Article
C2 - 29890874
AN - SCOPUS:85050562958
SN - 1476-7058
VL - 33
SP - 5
EP - 15
JO - Journal of Maternal-Fetal and Neonatal Medicine
JF - Journal of Maternal-Fetal and Neonatal Medicine
IS - 1
ER -